Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Down 14.8% in November

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 148,200 shares, a decline of 14.8% from the November 15th total of 173,900 shares. Approximately 3.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 90,200 shares, the short-interest ratio is presently 1.6 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Stock Performance

Shares of NASDAQ BCLI traded down $0.06 during mid-day trading on Friday, reaching $1.45. The company’s stock had a trading volume of 46,458 shares, compared to its average volume of 61,048. The stock has a 50-day moving average of $1.71 and a two-hundred day moving average of $3.85. The stock has a market capitalization of $8.27 million, a P/E ratio of -0.30 and a beta of 0.36. Brainstorm Cell Therapeutics has a 1-year low of $1.05 and a 1-year high of $11.89.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.